Thymosin Alpha-1
Peptide ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Thymosin Alpha-1 is a 28-amino-acid thymic peptide that modulates innate and adaptive immune responses. It is approved in some countries for hepatitis B or immune-adjuvant uses, but it is not FDA-approved in the United States. Evidence is strongest in selected infectious, sepsis, and hepatitis research settings, not general immune boosting.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Thymosin Alpha-1 is a peptide most often used for approved outside the us for selected immune indications, studied as an adjunct in hepatitis and sepsis, can modulate t-cell and dendritic-cell function. NutriStack rates the overall evidence as moderate. A typical adult dose is No FDA-approved US dose; approved-country protocols commonly use clinician-directed subcutaneous dosing such as 1.6 mg twice weekly for selected indications, commonly taken as regulated prescription product where approved; avoid research-grade peptides. This profile indexes 3 sources.
- Injection-site reaction
- Fatigue
- Headache
- Pregnancy and breastfeeding unless specialist-directed
- Autoimmune disease flare without specialist review
The bottom line
Evidence rating moderate. Most-documented uses: approved outside the us for selected immune indications, studied as an adjunct in hepatitis and sepsis, can modulate t-cell and dendritic-cell function. 3 sources indexed (2015–2020), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Thymosin alpha-1 influences dendritic-cell maturation, T-cell differentiation, NK-cell activity, antigen presentation, and cytokine balance through pathways that include TLR and interferon-related signaling. It tends to normalize dysregulated immunity rather than simply stimulate it, but clinical effects vary by disease state. Use with autoimmune disease, transplant immunosuppression, chemotherapy, or biologics requires specialist review.1,2
Dosing & protocol.
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.
What it actually costs.
Real-world pricing across three quality tiers. Assumes Regulated Thymalfasin Injection.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Full safety detail.
Side effects
- Injection-site reaction
- Fatigue
- Headache
- Nausea
- Flu-like symptoms
- Rash
- Potential immune flare in susceptible patients
Contraindications
- Pregnancy and breastfeeding unless specialist-directed
- Autoimmune disease flare without specialist review
- Solid-organ transplant or immunosuppressive therapy without transplant-team approval
- Active malignancy without oncology coordination
- Use of research-grade injectable products
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
1- 1The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trialsWu J et al. · Critical Care · 2016
Mortality signal favored thymosin alpha-1
Reviews & position papers
2- 2Thymosin alpha 1: A comprehensive review of the literatureKing R et al. · World Journal of Virology · 2020
Multiple immune indications reviewed
- 3Thymosin alpha-1 treatment in chronic hepatitis BZhao Y et al. · Expert Opinion on Biological Therapy · 2015
Immune-adjuvant role reviewed
Common questions.
Quick answers about Thymosin Alpha-1, drawn from the data on this page.
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino-acid thymic peptide that modulates innate and adaptive immune responses. It is approved in some countries for hepatitis B or immune-adjuvant uses, but it is not FDA-approved in the United States. Evidence is strongest in selected infectious, sepsis, and hepatitis research settings, not general immune boosting.
What is Thymosin Alpha-1 used for?
Commonly cited benefits of Thymosin Alpha-1 include: Approved outside the US for selected immune indications; Studied as an adjunct in hepatitis and sepsis; Can modulate T-cell and dendritic-cell function; Not FDA-approved in the US. NutriStack rates the overall evidence as moderate.
What is a typical dose of Thymosin Alpha-1?
A typical adult dose of Thymosin Alpha-1 is No FDA-approved US dose; approved-country protocols commonly use clinician-directed subcutaneous dosing such as 1.6 mg twice weekly for selected indications. The commonly recommended form is Regulated prescription product where approved; avoid research-grade peptides. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Thymosin Alpha-1?
Reported side effects include injection-site reaction, fatigue, headache, nausea, flu-like symptoms, rash. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Thymosin Alpha-1?
NutriStack rates this as Moderate, meaning several aligned RCTs or one large RCT plus supporting reviews. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Thymosin Alpha-1 in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.